Letrozole Significantly Improves Growth Potential in a Pubertal Boy With Growth Hormone Deficiency

Ping Zhou, MD; Bina Shah, MD; Kris Prasad, PhD; and Raphael David, MD


ABBREVIATIONS. AI, aromatase inhibitor; BMD, bone mineral density; GH, growth hormone; PTH, parathyroid hormone; IGF, insulin-like growth factor.

Estrogen plays a critical role for the pubertal growth spurt, skeletal maturation, and accrual and maintenance of bone mass in females as well as males.1–4 It is now evident that gene mutations of aromatase or estrogen receptor that result in impairment of estrogen production or action have similar phenotypes, including abnormally tall stature with eunuchoid proportions, a lack of pubertal growth spurt, unfused epiphyses, and osteopenia. Aromatase, encoded by the CYP19 gene located on chromosome 15q21.2 and expressed in bones, is the key enzyme for estrogen biosynthesis.2,4 It has been proposed that an aromatase inhibitor (AI) can be used to improve the final adult height in short pubertal boys. The hypothesis is that suppressing estrogen formation after the onset of puberty would delay the closure of the epiphyses, thus allowing for an extended period of growth without affecting the progression of androgenic development. Potential adverse effects of AIs, such as reduced bone mineral density (BMD), metabolic effects including a propensity for insulin resistance and dyslipidemia, and impairment of the hypothalamic-pituitary-gonadal axis, need to be considered.5 To date, a couple of studies, at least in the short term, indicate that the use of an AI is safe and promising.6–8

CASE REPORT

A white male was first seen for evaluation of short stature at 14 years 8 months old. He was healthy with no other medical problems, and his birth weight and length were reported as normal. Family history was unremarkable. His father’s height was 177.8 cm, and his mother’s height was 162.5 cm. His midparental target height was 176.7 cm (calculated as the average of parents’ heights + 6.55). His initial examination revealed the following: height, 143 cm (<3rd percentile; z score −2.94); upper/lower segment ratio, 1.0; weight, 44.5 kg (11th percentile); pubic hair, Tanner II; testicular volume, 4 to 6 mL; bilateral gynecomastia. Growth hormone (GH) deficiency was diagnosed after a standard comprehensive work-up (GH peak: 6.1 ng/mL; poststimulation), and GH treatment (0.3 mg/kg per week) was initiated at 15 years. The patient responded well (Fig 1). After 14 months of GH treatment, his height increased from 144.5 to 158 cm (z score: from −2.94 to −2.04), a gain of 13.5 cm (Table 1). However, although his puberty advanced to Tanner stage IV for pubic hair and testicular volume increased to 10 mL (Tanner III), his final adult-height prediction still remained 2 SDs below his target height. Letrozole (2.5 mg/day) was added at 16 years 9 months, after which letrozole was discontinued. He tolerated the treatment well. Gynecomastia resolved within a few months after combination therapy. Pubertal maturation proceeded to Tanner V (testicular volume: 15–20 mL). After 17 months of treatment, he gained an additional 10 to 168 cm, and his bone age advanced only 9 months (Greulich-Pyle method).9 His height z score improved further, from −2.04 to −1.08 (Table 1), and his adult-height prediction as estimated by the Bailey-Pineau method9 improved from 166.4 to 175.3 cm, corresponding to his target height. His upper/lower segment ratio was maintained at 1.0. Weight gain was noticed during the course of treatment (Fig 1). His BMI increased from 22 (76th percentile) to 24 (83rd percentile) after GH and to 27 (92nd percentile) after the addition of letrozole.9 Bone turnover markers were monitored. Four months after starting letrozole, the patient started to receive calcium supplementation (1200 mg/day) and vitamin D3 (400 IU/day) because of a mildly elevated intact parathyroid hormone (PTH) level of 69.9 pg/mL (reference: 10–65 pg/mL), low-normal 25-H vitamin D3 level of 78 pg/mL (reference: 27–71 pg/mL), and mildly elevated alkaline phosphatase level of 23 ng/mL (reference: 10–69 ng/mL), and mildly elevated intact parathyroid hormone (PTH) level of 23 ng/mL (reference: 10–69 ng/mL), and mildly elevated intact parathyroid hormone (PTH) level of 26 ng/mL (reference: 10–69 ng/mL). His height z score improved further, from −2.04 to −1.08 (Table 1), and his adult-height prediction as estimated by the Bailey-Pineau method improved from 166.4 to 175.3 cm, corresponding to his target height. His upper/lower segment ratio was maintained at 1.0. Weight gain was noticed during the course of treatment (Fig 1). His BMI increased from 22 (76th percentile) to 24 (83rd percentile) after GH and to 27 (92nd percentile) after the addition of letrozole.9 Bone turnover markers were monitored. Four months after starting letrozole, the patient started to receive calcium supplementation (1200 mg/day) and vitamin D3 (400 IU/day) because of a mildly elevated intact parathyroid hormone (PTH) level of 69.9 pg/mL (reference: 10–65 pg/mL), low-normal 25-H vitamin D3 level of 78 pg/mL (reference: 27–71 pg/mL), and mildly elevated alkaline phosphatase level of 23 ng/mL (reference: 10–69 ng/mL). Alkaline phosphatase was stable in the reference range, and PTH normalized after calcium and vitamin D supplementation. Bone markers including osteocalcin and N-telopeptide were decreased during therapy with letrozole and GH (see Table 1). Aerial bone density was determined by using a Hologic DEXA scanner (Bedford, MA), and the results were expressed as age-, gender-, and ethnicity-adjusted z scores. Although there was no pretreatment BMD study, a series of studies obtained at 4, 14, and 17 months during therapy actually showed some improvement of z score from −2.50 to −1.90.

As shown in Table 1, there was an initial increase in serum insulin-like growth factor 1 (IGF-I) from 124 to 824 ng/mL, undoubtedly reflecting the effects of GH therapy, which was then maintained in the high to upper-normal range (reference: 182–839 ng/mL). Basal follicle-stimulating hormone ranged from 9 to 22 mIU/mL (reference: 4–12 mIU/mL). Basal luteinizing hormone ranged from 5 to 7 mIU/mL (reference: 0.2–7.0 mIU/mL), both of which are in the high-normal range. Serum testosterone increased from 43 to 460 ng/dL after letrozole and then stabilized between 251 and 450 ng/dL (Tanner V; reference: 300–900 ng/dL). Serum
Fig 1. Growth chart.
<table>
<thead>
<tr>
<th>Patient Data</th>
<th>GH (0.3 mg/kg per wk)</th>
<th>Letrozole (2.5 mg/d)</th>
<th>Height, cm</th>
<th>z score of height</th>
<th>BMI</th>
<th>Tanner stage</th>
<th>Bone age</th>
<th>Predicted adult height, cm</th>
<th>IGFBP3, ng/mL</th>
<th>Testosterone, ng/dL</th>
<th>Estradiol, pg/mL</th>
<th>Intact PTH, pg/mL</th>
<th>ALP, U/L</th>
<th>osteocalcin, ng/mL</th>
<th>NTelopeptide, nM BCE/mM creatinine</th>
<th>BMD z-score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>15 y 15y 15y2m 16y2m 16y4m 16y6m 16y10m 17y2m 17y4m 17y6m 17y7m</td>
<td>14 mo 12 mo 0 mo 2 mo 4 mo 8 mo 12 mo 14 mo 17 mo</td>
<td>144.5 146.0 158.0 159.5 161.0 162.2 165.5 166.5 168.0</td>
<td>2.94 2.92 2.04 1.92 1.72 1.72 1.35 1.08 1.25</td>
<td>22.0 22.0 24.0 25.5 25.0 25.0 25.5 26.0 27</td>
<td>2 2 3 3 3 4 4 5 5</td>
<td>13y6m 14y 14y3m 14y9m</td>
<td>158.0 166.4 173.0 175.3</td>
<td>124.0 607.0 824.0 740.0 664.0 700.0 527.0 792.0 804.0</td>
<td>43.0 460.0 390.0 270.0 251.0 300.0 450.0 17.0 4.0 5.0 4.0 5.0</td>
<td>5.4 6.0 8.0 8.0 9.0 9.0</td>
<td>69.9 50.3 12.0 22.0</td>
<td>238.0 270.0 332.0 315.0 280.0 247.0 280.0 390.0 421.0 1.70 2.50 1.90</td>
<td>2.90 2.90 2.90 2.90 2.90 2.90 2.90 2.90 2.90</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>15 y 15y 15y2m 16y2m 16y6m 16y10m 17y2m 17y4m 17y6m 17y7m</td>
<td>13 y 13.5 14 14 14 14 14 14 14</td>
<td>144.5 146.0 158.0 159.5 161.0 162.2 165.5 166.5 168.0</td>
<td>2.94 2.92 2.04 1.92 1.72 1.72 1.35 1.08 1.25</td>
<td>22.0 22.0 24.0 25.5 25.0 25.0 25.5 26.0 27</td>
<td>2 2 3 3 3 4 4 5 5</td>
<td>13y6m 14y 14y3m 14y9m</td>
<td>158.0 166.4 173.0 175.3</td>
<td>124.0 607.0 824.0 740.0 664.0 700.0 527.0 792.0 804.0</td>
<td>43.0 460.0 390.0 270.0 251.0 300.0 450.0 17.0 4.0 5.0 4.0 5.0</td>
<td>5.4 6.0 8.0 8.0 9.0 9.0</td>
<td>69.9 50.3 12.0 22.0</td>
<td>238.0 270.0 332.0 312.0 280.0 247.0 280.0 390.0 421.0 1.70 2.50 1.90</td>
<td>2.90 2.90 2.90 2.90 2.90 2.90 2.90 2.90 2.90</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
treatment boys with delayed puberty. After 18 months of treatment, their letrozole group increased the average predicted final adult height by 5.1 cm. In our own patient treated with comparable doses of letrozole in addition to GH, the predicted final height increased by 8.9 cm. It is encouraging to note that in the patients of Dunkel and co-workers, no detrimental effects on BMD were found.7

Gonadotropin-releasing hormone analog (GnRHa) therapy has been used for the treatment of short stature in pubertal boys and girls.14 Detrimental effects of GnRHAs on body composition, muscle strength, and protein, lipid, and calcium metabolism, in addition to inhibiting virilization in males, have been the subject of several publications.15–17 These effects make the use of these analogs unsuitable in the long term if the sole purpose of treatment is to increase final height.

The conclusion from a recent study by Yanovski et al stated that “treatment with an LHRH [luteinizing hormone-releasing hormone] agonist for 3.5 years increases adult height by 0.6 SD in adolescents with very short stature but substantially decreases bone mineral density. Such treatment cannot be routinely recommended to augment height in adolescents with normally timed puberty.”18(p908) Thus, the use of a potent selective aromatase blocker offers the advantage of continued virilization and maintenance of pubertal body composition5,7 in boys while potentially delaying skeletal maturation. We therefore believe that the use of an AI with or without GH is a better option for enhancing the growth potential of short pubertal boys. Although our case and the Finnish studies showed a short-term benefit using an AI, long-term controlled studies are necessary to establish its safety and efficacy.

REFERENCES

Letrozole Significantly Improves Growth Potential in a Pubertal Boy With Growth Hormone Deficiency

Ping Zhou, Bina Shah, Kris Prasad and Raphael David

Pediatrics 2005;115:e245; originally published online January 14, 2005; DOI: 10.1542/peds.2004-1536

Updated Information & Services
including high resolution figures, can be found at:
/content/115/2/e245.full.html

References
This article cites 18 articles, 1 of which can be accessed free at:
/content/115/2/e245.full.html#ref-list-1

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):

Endocrinology
/cgi/collection/endocrinology_sub

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
/site/misc/Permissions.xhtml

Reprints
Information about ordering reprints can be found online:
/site/misc/reprints.xhtml
Letrozole Significantly Improves Growth Potential in a Pubertal Boy With Growth Hormone Deficiency
Ping Zhou, Bina Shah, Kris Prasad and Raphael David
Pediatrics 2005;115:e245; originally published online January 14, 2005;
DOI: 10.1542/peds.2004-1536

The online version of this article, along with updated information and services, is located on the World Wide Web at:
/content/115/2/e245.full.html